- Home
- ATHA vs IZM Comparison
ATHA vs IZM Comparison
Compare ATHA & IZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- IZM
- Stock Information
- Founded
- ATHA 2011
- IZM 2011
- Country
- ATHA United States
- IZM China
- Employees
- ATHA N/A
- IZM N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- IZM Consumer Electronics/Video Chains
- Sector
- ATHA Health Care
- IZM Consumer Discretionary
- Exchange
- ATHA Nasdaq
- IZM Nasdaq
- Market Cap
- ATHA 18.2M
- IZM 16.6M
- IPO Year
- ATHA 2020
- IZM 2023
- Fundamental
- Price
- ATHA $4.72
- IZM $1.10
- Analyst Decision
- ATHA
- IZM
- Analyst Count
- ATHA 0
- IZM 0
- Target Price
- ATHA N/A
- IZM N/A
- AVG Volume (30 Days)
- ATHA 25.6K
- IZM 662.9K
- Earning Date
- ATHA 11-06-2025
- IZM 10-24-2025
- Dividend Yield
- ATHA N/A
- IZM N/A
- EPS Growth
- ATHA N/A
- IZM N/A
- EPS
- ATHA N/A
- IZM 0.10
- Revenue
- ATHA N/A
- IZM $187,048,691.00
- Revenue This Year
- ATHA N/A
- IZM N/A
- Revenue Next Year
- ATHA N/A
- IZM N/A
- P/E Ratio
- ATHA N/A
- IZM $9.80
- Revenue Growth
- ATHA N/A
- IZM 5.12
- 52 Week Low
- ATHA $2.20
- IZM $0.92
- 52 Week High
- ATHA $6.79
- IZM $2.74
- Technical
- Relative Strength Index (RSI)
- ATHA 61.31
- IZM 31.08
- Support Level
- ATHA $4.31
- IZM $0.92
- Resistance Level
- ATHA $4.95
- IZM $1.09
- Average True Range (ATR)
- ATHA 0.37
- IZM 0.17
- MACD
- ATHA -0.04
- IZM 0.02
- Stochastic Oscillator
- ATHA 73.60
- IZM 23.15
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About IZM ICZOOM Group Inc.
ICZOOM Group Inc. operates an e-commerce platform selling electronic components to SMEs in China across consumer electronics, IoT, automotive, and industrial control sectors. It offers two main product categories: semiconductor products, including integrated circuits and optoelectronics, and electronic equipment and tools such as electromechanical and MRO supplies. The company also provides services like customs clearance, temporary warehousing, and logistics, earning additional commission fees. The majority of its revenue comes from electronic component sales.